Literature DB >> 9352692

Willingness to pay for reduced incontinence symptoms.

M Johannesson1, R M O'Conor, G Kobelt-Nguyen, A Mattiasson.   

Abstract

OBJECTIVE: To measure the willingness to pay for a reduction in the number of micturitions and urinary leakages for patients with urge incontinence. PATIENTS AND METHODS: A self-administered questionnaire with a binary willingness-to-pay question was administered to 541 patients in Sweden with urge or mixed incontinence; 461 questionnaires were returned. The reduction in micturitions and urinary leakages valued in the willingness-to-pay question was varied randomly between 25% and 50% in two different subsamples. Information was also collected about the number of micturitions and urinary leakage, health-related quality of life and socio-economic characteristics of the patients in the study.
RESULTS: Quality of life was significantly related to the severity of the symptoms and was worse than that of the sex- and age-matched general Swedish population. The median (mean) willingness to pay per month was 240 (530) Swedish krona (SEK, 1 Pound = SEK 11.50) for a 25% reduction in micturitions and leakages and SEK 470 (1030) for a 50% reduction in micturitions and leakages. As hypothesized, the willingness to pay was significantly related to the size of the reduction in micturitions and leakages, the initial number of micturitions and leakages, and income.
CONCLUSIONS: Patients with incontinence problems are willing to pay substantial amounts for a reduction in the number of micturitions and leakages.

Entities:  

Mesh:

Year:  1997        PMID: 9352692     DOI: 10.1046/j.1464-410x.1997.00420.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  20 in total

1.  Willingness to pay for mammography: item development and testing among five ethnic groups.

Authors:  T H Wagner; T W Hu; G V Dueñas; R J Pasick
Journal:  Health Policy       Date:  2000-09       Impact factor: 2.980

Review 2.  What's a 'cure'? Patient-centred outcomes of treatments for stress urinary incontinence.

Authors:  R M Freeman
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-09-12

Review 3.  Using the stated preference technique for eliciting valuations: the role of the payment vehicle.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

Review 4.  Economics of lower urinary tract symptoms (LUTS) in older people.

Authors:  U Azam; M Castleden; D Turner
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.

Authors:  P Abrams; J Malone-Lee; B Jacquetin; J J Wyndaele; T Tammela; U Jonas; A Wein
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Urge incontinence. Quality of life and patients' valuation of symptom reduction.

Authors:  R M O'Conor; M Johannesson; S L Hass; G Kobelt-Nguyen
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

7.  The "costs" of urinary incontinence for women.

Authors:  Leslee L Subak; Jeanette S Brown; Stephen R Kraus; Linda Brubaker; Feng Lin; Holly E Richter; Catherine S Bradley; Deborah Grady
Journal:  Obstet Gynecol       Date:  2006-04       Impact factor: 7.661

8.  Do women with overactive bladder have realistic expectations for therapy?

Authors:  Arasee Renganathan; Dudley Robinson; Linda Cardozo; Sushma Srikrishna; Rufus Cartwright
Journal:  Int Urogynecol J       Date:  2010-04       Impact factor: 2.894

9.  The cost utility of solifenacin in the treatment of overactive bladder.

Authors:  Leona Hakkaart; Paul Verboom; Richard Phillips; Maiwenn J Al
Journal:  Int Urol Nephrol       Date:  2008-08-15       Impact factor: 2.370

Review 10.  The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.

Authors:  Danny Ulahannan; Adrian Wagg
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.